After a lung cancer diagnosis, the hospital takes a sample of tissue and runs all sorts of tests on it. Among them is something called the "PD-L1" test, and because the name sounds unfamiliar, many people just let it pass without paying attention. In truth, once you realize that this one test can largely steer the direction of your treatment, you start listening more closely.
PD-L1 is a kind of protein that acts like a brake, keeping our immune cells from attacking the cancer. When cancer cells coat their surface with plenty of it, even an immune cell that approaches will think, "this one is not an enemy," and simply pass it by. Immunotherapy (an immune checkpoint inhibitor) is precisely the drug that releases this brake. So by checking in advance how much PD-L1 is attached to the cancer cells, you get a sense of how likely this drug is to work.
The test result is usually given as a "TPS" or a percentage. It is divided into ranges, like 0%, 1 to 49%, and 50% or more, and the higher the number, the greater the chance of a good response to immunotherapy alone. So if it is over 50%, treatment may begin with immunotherapy alone, without chemotherapy, while if it is lower, the combination is adjusted, for example using chemotherapy and immunotherapy together. One patient once asked, "why is the person in the next bed on a different drug?" and it turned out that the two of them had different PD-L1 levels. This is the reason prescriptions diverge from person to person even with the same lung cancer.
The test itself is often done using the sample already taken during the biopsy, so you usually do not have to be poked again separately. However, if too little tissue was obtained or the sample is old, the level may not come out accurately, and in that case they may ask to obtain tissue again. And one thing to remember: a low PD-L1 level does not mean that immunotherapy will not work at all. The number is only a reference line showing the likelihood; in reality, the decision is made by weighing other things together, such as whether there are other gene mutations like EGFR, the patient condition, and the type of cancer.
So in the consultation room, try asking, "what percentage did my PD-L1 come out to?" It greatly helps you understand why your treatment was put together the way it was. There is no need to be elated or downcast over the number, but holding one more map of your own body does make you feel considerably more reassured.
This article is a general explanation meant to aid understanding. Please be sure to consult your own doctor about the actual interpretation of the test and treatment decisions.